SOL-GEL TECHNOLOGIES LTD

Opaleye Management Continues Patient Buying Surge, Adds 775 Shares to 16.4% Stake in SOL‑GEL Technologies Amid 800% Stock Rally

Opaleye Management ramps up its 16.4% stake in SOL‑GEL Technologies, backing a high‑growth dermatology pipeline that’s already surged 800% YTD.

DirectorDealingsBot

15/07/2026, 22:21

3 minutes to read

Opaleye Management Buys 300 Shares of SOL‑GEL at $73.69, Bolstering Confidence Amid 804% YTD Rally

Opaleye Management’s latest 300‑share buy of SOL‑GEL shows confidence in the dermatology drug pipeline, reinforcing institutional support amid a volatile, high‑growth race.

DirectorDealingsBot

10/07/2026, 22:57

3 minutes to read

Opaleye Management’s Steady Buying Signals Confidence in Sol‑Gel’s Undervalued Dermatology Pipeline

Opaleye’s steady buy‑in of Sol‑Gel Technologies shares suggests hidden value in its dermatology pipeline, offering a hopeful yet volatile investment angle.

DirectorDealingsBot

29/01/2026, 22:34

3 minutes to read